863-866
Editorial
Fotemustine and recurrent glioblastoma: possible new opportunities for an old drug
Raffaele Addeo, M. Serena De Santi, Salvatore Del Prete and Michele Caraglia
867-875
Original Article
Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4′-methanol-bisbenzonitrile in vitro
Seongwook Jeong, Margaret M. Woo, David A. Flockhart and Zeruesenay Desta
877-883
Original Article
Dose-finding study of docetaxel, oxaliplatin, and S-1 for patients with advanced gastric cancer
Dae Young Zang, Dae Hyun Yang, Min-Jeong Kim, Kyung Mi Jang and Se Won Hwang, et al.
885-892
Original Article
Downregulation of matrix metalloprotease-9 and urokinase plasminogen activator by TX-1877 results in decreased tumor growth and metastasis on xenograft model of rectal cancer
Kotaro Miyake, Mitsuo Shimada, Masanori Nishioka, Koji Sugimoto and Erdenebulgan Batmunkh, et al.
893-899
Original Article
Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group
Pasquale Comella, Vito Lorusso, Luigi Maiorino, Rossana Casaretti and Michele Cannone, et al.
901-905
Original Article
Bleomycin, vinorelbine and trofosfamide in relapsed stage IV cutaneous malignant melanoma patients
Jens Atzpodien, Lars Morawek, Michael Fluck and Martina Reitz
907-916
Original Article
Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma
Gaetano Corazzelli, Gaetana Capobianco, Manuela Arcamone, Pier Ferruccio Ballerini and Emilio Iannitto, et al.
917-924
Original Article
Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer
Myung Hee Chang, Kyoung Ha Kim, Hyun Jung Jun, Hyo Song Kim and Seong Yoon Yi, et al.
925-933
Original Article
The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines
Jackie Perry, Thomas Powles, Jonathan Shamash, Arthi Veerupillai and Eva McGrowder, et al.
935-944
Original Article
A phase I study of gemcitabine given via intrahepatic pump for primary or metastatic hepatic malignancies
Archie N. Tse, Nian Wu, Dina Patel, Dana Haviland and Nancy Kemeny
945-952
Original Article
Open AccessAnalysis of feasibility and toxicity of concurrent chemoradiotherapy with S-1 for locally advanced squamous cell carcinoma of the head and neck in elderly cases and/or cases with comorbidity
Mamoru Tsukuda, Junichi Ishitoya, Yasukazu Mikami, Hideki Matsuda and Choichi Horiuchi, et al.
953-960
Original Article
Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin
Jong Gwang Kim, Yee Soo Chae, Sang Kyun Sohn, Joon Ho Moon and Hun Mo Ryoo, et al.
961-969
Original Article
Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function
Li-yang Tao, Yong-ju Liang, Fang Wang, Li-ming Chen and Yan-yan Yan, et al.
971-980
Original Article
Chemoprotection and enhancement of cancer chemotherapeutic efficacy of cyclophosphamide in mice bearing Ehrlich ascites carcinoma by diphenylmethyl selenocyanate
Pramita Chakraborty, Ugir Hossain Sk and Sudin Bhattacharya
981-991
Original Article
Delivery of high levels of anti-proliferative nucleoside triphosphates to CYP3A-expressing cells as a potential treatment for hepatocellular carcinoma
Deidre A. MacKenna, Annika Montag, Serge H. Boyer, David L. Linemeyer and Mark D. Erion
993-999
Original Article
Open AccessDistinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers
E. Izbicka, A. Diaz, R. Streeper, M. Wick and D. Campos, et al.
1001-1007
Original Article
Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy
Zhao-Hui Huang, Dong Hua and Xiang Du
1009-1020
Original Article
In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer
Donato Cosco, Alessandra Bulotta, Monica Ventura, Christian Celia and Teresa Calimeri, et al.
1021-1027
Original Article
A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial
Carmela Pisano, Alessandro Morabito, Roberto Sorio, Enrico Breda and Rossella Lauria, et al.
1029-1038
Original Article
Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents
Leslie S. Kurtzberg, Stephanie D. Roth, Rebecca G. Bagley, Cecile Rouleau and Min Yao, et al.
1039-1046
Original Article
Open AccessPerturbation of DNA repair pathways by proteasome inhibitors corresponds to enhanced chemosensitivity of cells to DNA damage-inducing agents
Takashi Takeshita, Wenwen Wu, Ayaka Koike, Mamoru Fukuda and Tomohiko Ohta
1047-1052
Original Article
The acute effects of CMF-based chemotherapy on maxillary periodontal microcirculation
Dan M. J. Milstein, Rick Bezemer, Jérôme A. H. Lindeboom and Can Ince
1053-1058
Short Communication
A sphingosine kinase inhibitor induces cell death in temozolomide resistant glioblastoma cells
Meryem Bektas, Stewart P. Johnson, William E. Poe, Darell D. Bigner and Henry S. Friedman